Banque Pictet & Cie SA cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 86.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 64,945 shares of the company’s stock after selling 407,438 shares during the quarter. Banque Pictet & Cie SA’s holdings in Teva Pharmaceutical Industries Limited were worth $2,148,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Advisory Services Network LLC acquired a new position in Teva Pharmaceutical Industries Limited during the 1st quarter worth approximately $163,000. Grimes & Company Inc. boosted its position in Teva Pharmaceutical Industries Limited by 27.3% during the 1st quarter. Grimes & Company Inc. now owns 49,880 shares of the company’s stock worth $1,601,000 after acquiring an additional 10,692 shares during the last quarter. Nwam LLC boosted its position in Teva Pharmaceutical Industries Limited by 54.5% during the 1st quarter. Nwam LLC now owns 16,080 shares of the company’s stock worth $516,000 after acquiring an additional 5,674 shares during the last quarter. Pillar Pacific Capital Management LLC boosted its position in Teva Pharmaceutical Industries Limited by 10.0% during the 1st quarter. Pillar Pacific Capital Management LLC now owns 91,688 shares of the company’s stock worth $2,942,000 after acquiring an additional 8,359 shares during the last quarter. Finally, CT Mason boosted its position in Teva Pharmaceutical Industries Limited by 1.6% during the 1st quarter. CT Mason now owns 74,155 shares of the company’s stock worth $2,380,000 after acquiring an additional 1,160 shares during the last quarter. Institutional investors and hedge funds own 56.87% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Shares Sold by Banque Pictet & Cie SA” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://theolympiareport.com/2017/09/04/teva-pharmaceutical-industries-limited-teva-shares-sold-by-banque-pictet-cie-sa.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.90 on Monday. The firm’s 50-day moving average price is $23.15 and its 200 day moving average price is $29.75. The company’s market cap is $16.15 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $15.32 and a 52-week high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.25 earnings per share. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 2.14%. Teva Pharmaceutical Industries Limited’s payout ratio is presently -15.36%.

A number of equities analysts have weighed in on the company. Credit Suisse Group set a $39.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target for the company in a research report on Monday, July 24th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BidaskClub downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Four investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $34.50.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.